Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1944 in healthy adults
NCT03829384Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial in chikungunya virus infection comparing mRNA-1944 with Placebo (2 arms). Primary endpoint: Frequency of adverse events, serious adverse events, adverse events of special interest and laboratory abnormalities at 13 months. Started Jan 2019; status: completed.
02
Drugs
mRNA-1944
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT03829384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829384.